We provide you with 20 years of free, institutional-grade data for AKBA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AKBA. Explore the full financial landscape of AKBA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Akebia Therapeutics, Inc(NASDAQ:AKBA) 
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the tre...
The information provided in this report about AKBA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.